Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2017

View Archived Issues

Roche describes novel HBsAg secretion inhibitors

Bristol-Myers Squibb presents new TGF-beta receptor type-1 inhibitors

Eisai reflects on key achievements of third quarter of fiscal 2016

Novartis initiates phase I trial of HKT-288 in solid tumors

Reduced SOD1 gene expression as a biomarker in patients with primary glaucoma

Ariad files for European marketing approval of brigatinib

FDA approves IND for light-activated drug to treat ocular melanoma

Researchers announce discovery of first blood biomarker for MS

Galena reports positive outcome of futility assessment of NeuVax trials

Sobi announces potential sale of the partner products business area

In situ activation of platelets enhances anti-PD-L1 delivery and reduces post-surgical recurrence

Activation of microRNA-1182 may induce melanoma apoptosis

Exosome Diagnostics and Merck KGaA sign agreement to advance drug development efforts

First-in-human trial demonstrates efficacy of 68Ga-BBN-RGD for prostate cancer diagnosis and staging

Sirnaomics initiates first-in-human study of STP-705

Bayer discloses novel isocitrate dehydrogenase (NADP+) inhibitors

Institute of Experimental Botany identifies apoptosis inducers/ROS inhibitors

Following successful phase I testing, CF drug SPX-101 will move to phase II

FDA lifts partial clinical hold on phase III study of DCVax-L

Takeda discovers prostanoid EP4 receptor antagonists

Renova announces development plans for stresscopin

Enanta patents novel benzodiazepine derivatives

BioTime acquires ophthalmology assets from University of Pittsburgh

Isogenica grants license to Maverick Therapeutics for antibody technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...